Drugs for COVID-19
CURRENT
ISSUE
1654

The FDA has approved tirzepatide (Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes. Tirzepatide, which is injected subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the US. Selective GIP receptor agonists are not available in the US; GLP-1 receptor agonists have been available for years.

GLP-1 RECEPTOR AGONISTS ―...  Continue reading

Coming Soon
Drugs for Treatment and Prevention of Venous Thromboembolism
Oteseconazole (Vivjoa) for Vulvovaginal Candidiasis
Donepezil Transdermal (Adlarity) for Alzheimer's
Lumateperone (Caplyta) for Bipolar Depression